期刊文献+

瑞巴派特联合埃索美拉唑治疗非甾体抗炎药所致胃炎的疗效观察 被引量:3

下载PDF
导出
摘要 目的:探讨瑞巴派特联合埃索美拉唑治疗非甾体抗炎药(NSAIDs)所致胃炎的临床效果。方法:选取117例因长期服用非甾体抗炎药导致腹胀、腹痛、嗳气、反酸等症状,经胃镜检查确诊为胃炎而就诊的患者为研究对象,将其随机分为观察组(瑞巴派特联合埃索美拉唑组)61例和对照组(瑞巴派特组)56例,药物治疗2个月后,对两组患者治疗后临床症状评分及疗效评价进行统计及比较。结果:观察组症状评分和疗效评价与对照组比较存在统计学差异(P<0.05)。结论:瑞巴派特联合埃索美拉唑用于NSAIDs胃炎的临床疗效优于单用瑞巴派特,值得推广使用。
作者 李学良
出处 《中国民康医学》 2014年第23期72-73,共2页 Medical Journal of Chinese People’s Health
  • 相关文献

参考文献3

二级参考文献21

  • 1Stedman CAM, Barclay ML. Review article : comparison of the pharmacoki - netics,acid suppression and efficacy of proton pump inhibitors[ J]. Aliment Pharmacol Ther,2000,14 ( 8 ) :963 - 978.
  • 2彭南安.不同抗酸药防治非甾体类抗炎药胃粘膜损伤的疗效观察[J].实用药物与临床,2007,10(4):212-214. 被引量:11
  • 3Morgner A, Miehlke S, Labenz J. Esome?prazole , prevention and treatment of NSAID - induced symptoms and ulcers [J]. Expert Opin Pharmacother, 2007, 8 (7): 975 - 988.
  • 4Matsui H, Shimokawa 0, Kaneko T, et aI. The pathophysiology of non - steroidal anti - inflammatory drug (NSAID) - induced mu?cosal injuries in stomach and small intestine [J]. J Clin Biochem Nutr, 2011, 48 (2): 107 -111.
  • 5Tiihonen K, Tynkkynen S, Ouwehand A, et aI. The effect of ageing with and. without non - steroidal anti - inflammatory drugs on gastrointestinal microbiology and immunology [J]. Br J Nutr, 2008, 100 (1): 130- 137.
  • 6Targownik LE, Metge CJ, Leung S. Underu?tilization of gastroprotective strategies in aspirin users at increased risk of upper gastrointestinal complications [J]. Aliment Pharmacol Ther, 2008, 28 (1): 88 -96.
  • 7Koch TR, Petro A, Darrabie M, et aI. Effects of esomeprazole magnesium on nonste?roidal anti - inflammatory drug gastropathy [J]. Dig Dis Sci, 2005, 50 (1): 86- 93.
  • 8Miwa H, Osada T, Nagahara A, et aI. Effect of a gastro - protective agent, rebamip?ide, on symptom improvement in patients with functional dyspepsia: a double - blind placebo - controlled study in Japan [J]. J Gastroenterol Hepatol, 2006, 21 (12): 1826 -1831.
  • 9BHATT D L, SCHEIMAN J, ABRAHAM N S. AC- CF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelett her- apy and NSAID use:a report of the American college of cardiology foundation task force on clinical expert consensus documents [J]. Circulation, 2008, 118.. 1894 -1909.
  • 10LOU H Y, CHANG C C, SHEN M T, et al. Optimal dose regimens of esomeprazole for gastric acid suppres- sion with minimal influence of the CYP2C19 ploymor phism[J]. Eur J Clin Pharmacol, 2009,65 . 55-- 64.

共引文献30

同被引文献14

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部